Skip to main content

Advertisement

Log in

Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

An Erratum to this article was published on 08 September 2011

Abstract

Background

The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes.

Objective

The objective of this study was to investigate the pharmacokinetics and the placental transfer of metformin in pregnant women with PCOS.

Patients and methods

Eight pregnant women with PCOS taking 850 mg metformin every 12 h during the third trimester of pregnancy were evaluated. Maternal blood samples were collected at steady state during the dose interval (0–12 h). Maternal and umbilical cord blood samples were also obtained at delivery. Metformin plasma concentrations were analyzed by high-performance liquid chromatography, and pharmacokinetic parameters were determined using a non-compartmental model. Data are reported as median and minimum and maximum values.

Results

Metformin pharmacokinetic parameters were: t½, 3.8 (2.8–5.4) h; tmax, 2.0 (0.5–3.0) h; Cmax, 1.4 (0.5–2.1) mg/L; Cmean, 0.5 (0.2–0.9) mg/L; AUC0–12, 6.4 (1.1–9.2) mg h/L; Cl/f, 105 (60–274) L/h; Vd/f, 551 (385–1173) L; median fluctuation, 89 (79–95)%. Umbilical/maternal metformin plasma concentration ratios were 0.7 (0.4–1.3).

Conclusion

Metformin oral clearance (Cl/f) had increased in our patients relative to nonpregnant healthy volunteers or diabetic patients. Therefore, lower plasma metformin concentrations were observed for nondiabetic pregnant women with PCOS. Future studies should be conducted to demonstrate the therapeutic efficacy of metformin during pregnancy. Caution is warranted as umbilical/maternal metformin plasma concentrations ratios of around 0.7 require metformin dosage adjustment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861

    Article  PubMed  CAS  Google Scholar 

  2. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574–579

    Article  PubMed  CAS  Google Scholar 

  3. Tulppala M, Stenman UH, Cacciatore B, Ylikorkala O (1993) Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br J Obstet Gynaecol 100:348–352

    Article  PubMed  CAS  Google Scholar 

  4. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87:524–529

    Article  PubMed  CAS  Google Scholar 

  5. Radon PA, McMahon MJ, Meyer WR (1999) Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 94:194–197

    Article  PubMed  CAS  Google Scholar 

  6. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T (2002) Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 54:94–98

    Article  PubMed  CAS  Google Scholar 

  7. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691–696

    Article  PubMed  CAS  Google Scholar 

  8. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 87:569–574

    Article  PubMed  CAS  Google Scholar 

  9. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L (2002) Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17:2858–2864

    Article  PubMed  CAS  Google Scholar 

  10. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P (2004) Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21:829–836

    Article  PubMed  CAS  Google Scholar 

  11. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P (2004) Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 19:1323–1330

    Article  PubMed  CAS  Google Scholar 

  12. Little BB (1999) Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 93:858–868

    Article  PubMed  CAS  Google Scholar 

  13. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GDV, Clark SM, Risler L, Wang J, Kelly EJ, Shen DD, Hebert MF (2010) Pharmacokinetics of metformin during pregnancy. Drug Met Dispos 38:833–840

    Article  CAS  Google Scholar 

  14. Charles B, Norris R, Xiao X, Hague W (2006) Population Pharmacokinetics of metformin in late pregnancy. Ther Drug Monit 28:67–72

    Article  PubMed  CAS  Google Scholar 

  15. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH (1996) Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36:1012–1021

    Article  PubMed  CAS  Google Scholar 

  16. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246

    PubMed  CAS  Google Scholar 

  17. Hughes RCE, Gardiner SJ, Begg EJ, Zhang M (2006) Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med 23:323–326

    Article  PubMed  CAS  Google Scholar 

  18. Mikola M, Hiilesman V, Halttunen M, Suhonen L, Tiitnen A (2001) Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16:226–229

    Article  PubMed  CAS  Google Scholar 

  19. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647–654

    Article  PubMed  CAS  Google Scholar 

  20. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722

    Article  PubMed  CAS  Google Scholar 

  21. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549

    Article  PubMed  CAS  Google Scholar 

  22. Loebstein R, Lalkin A, Koren G (1997) Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328–343

    Article  PubMed  CAS  Google Scholar 

  23. Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M (2008) Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol 136:29–33

    Article  PubMed  CAS  Google Scholar 

  24. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GDV, Ahmed MS (2010) Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 202:383.e1–383.e7

    Article  Google Scholar 

  25. Vanki E, Zahlsen K, Spigset O, Carlsen SM (2005) Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 83:1575–1578

    Article  Google Scholar 

  26. Amin R, Hossain MZ, Miah T, Yasmin R, Chowdhury FI, Hoque A (2010) Are oral hypoglycemic agents contraindicated in pregnancy? J Bangladesh Coll Phys Surg 28:129–131

    Google Scholar 

Download references

Acknowledgments

The authors are grateful to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Fundação de Apoio a Pesquisa e Assistência do HCFMRP-USP (FAEPA) and to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for financial support and for granting research fellowships.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ricardo Carvalho Cavalli.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00228-011-1116-2

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Oliveira Baraldi, C., Lanchote, V.L., de Jesus Antunes, N. et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol 67, 1027–1033 (2011). https://doi.org/10.1007/s00228-011-1053-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-011-1053-0

Keywords

Navigation